A large subset of gliomas are now defined based on the presence/absence of isocitrate dehydrogenase (IDH) mutation, O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation, and 1p/19q co-deletion, which can help in management and stratification of glioma patients (5). This evidence concerns the gene IDH1 and central nervous system cancer.